Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immunome Inc IMNM

Healthcare Biotechnology
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMNM)

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Business Wire April 5, 2024

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Business Wire March 28, 2024

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire March 26, 2024

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Business Wire March 26, 2024

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Business Wire March 7, 2024

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Business Wire March 1, 2024

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Business Wire February 20, 2024

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire February 20, 2024

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Business Wire February 16, 2024
View More News ››

Opinion & Analysis (NDAQ:IMNM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMNM)

CAN IMMUNOME BOUNCE BACK FROM CLINICAL HOLD ON IMM-BCP-01

$IMNM   Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company, announced the receipt of a clinical hold letter from the U...
AviseAnalytics - January 17, 2022
View more Bullboard ››

North Arrow Minerals Inc.

North Arrow Minerals Inc.

North Arrow Minerals Inc. is a Canada-based exploration company. The Company is focused on the identification and evaluation ...
View More »